PAREXEL (NASDAQ:PRXL) Change of Rating

New York-listed Parexel (NASDAQ:PRXL), was upgraded by stock research analysts at Goldman Sachs. The firm upgraded its rating on the $4.03B market cap company to “Neutral” from a previous “Sell”.

Despite this stock rating upgrade NASDAQ:PRXL is at the moment trading 0.00% lower at $79.31 as of 2:04 AM New York time. PAREXEL shares have [From2] 0% in the last 200 days, while the S&P500 has increased 6.00% in the same time period.

According to data compiled by Thomson Reuters, PAREXEL (NASDAQ:PRXL)’s stock is covered by 11 equity analysts across the Street, with 1 analysts giving it a Sell rating, 9 a Buy rating, while 6 consider it a Hold. The 12-month consensus target price for the stock is $68.68, which reflects an downside potential of 13.40% over the current price.

Institutional Ownership

Cryder Capital Partners Llp had the largest stake with ownership of 180,206 shares as of Q2 2015 for 7.34% of the stock exposure. Lloyds Banking Group Plc is another very bullish investment manager who is possessing 3,950 shares of PAREXEL or 2.46% of their stock exposure. Moreover, Jhl Capital Group Llc have 2.14% of their stock exposure invested in the company for 470,000 shares. The Massachusetts-based fund Aristotle Capital Boston Llc disclosed it had acquired so far a stake worth about 2.03% of the investment manager’s stock portfolio in PAREXEL. The New York-based fund Dalton Greiner Hartman Maher & Co is also positive about the stock, possessing 164,242 shares or 2.02% of their stock exposure.

PAREXEL (NASDAQ:PRXL) Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).

PAREXEL (NASDAQ:PRXL) closed at $79.31 yesterday. A total of shares of the company’s stock traded hands. This is down from average of 1.07M shares. PAREXEL has a 52 week low of $51.16 and a 52 week high of $80.2. The company has a market cap of $4.03B and a P/E ratio of 34.96.

Get the latest PAREXEL (NASDAQ:PRXL) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post New York: PAREXEL (NASDAQ:PRXL) Rating Outlook Upped to “Neutral” by Analysts at Goldman Sachs. Lost Its “Sell” Rating appeared first on Octafinance.